Collegium Pharmaceutical Book Value Per Share Growth & History (COLL)
Collegium Pharmaceutical's book value per share was $9.51 for fiscal 2025.
View full Collegium Pharmaceutical company overviewCollegium Pharmaceutical annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.51 | $2.24 | +30.71% |
| 2024 | 2024-12-31 | $7.28 | $1.15 | +18.69% |
| 2023 | 2023-12-31 | $6.13 | $0.38 | +6.54% |
| 2022 | 2022-12-31 | $5.76 | -$0.27 | −4.53% |
| 2021 | 2021-12-31 | $6.03 | $0.65 | +12.18% |
| 2020 | 2020-12-31 | $5.37 | $2.78 | +107.04% |
| 2019 | 2019-12-31 | $2.60 | -$0.16 | −5.71% |
| 2018 | 2018-12-31 | $2.75 | -$0.42 | −13.31% |
| 2017 | 2017-12-31 | $3.18 | -$1.42 | −30.87% |
| 2016 | 2016-12-31 | $4.59 | $0.49 | +12.00% |
| 2015 | 2015-12-31 | $4.10 | $92.90 | — |
| 2014 | 2014-12-31 | -$88.80 | -$17.95 | — |
| 2013 | 2013-12-31 | -$70.85 | — | — |
Collegium Pharmaceutical quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.60 | $2.24 | +30.40% |
| Q1 2026 | 2026-03-31 | $9.64 | $2.34 | +32.13% |
| Q4 2025 | 2025-12-31 | $9.51 | $2.24 | +30.71% |
| Q3 2025 | 2025-09-30 | $8.70 | $1.43 | +19.63% |
| Q2 2025 | 2025-06-30 | $7.36 | $0.66 | +9.83% |
| Q1 2025 | 2025-03-31 | $7.30 | $0.50 | +7.41% |
| Q4 2024 | 2024-12-31 | $7.28 | $1.15 | +18.69% |
| Q3 2024 | 2024-09-30 | $7.27 | $1.86 | +34.36% |
| Q2 2024 | 2024-06-30 | $6.70 | $0.92 | +15.86% |
| Q1 2024 | 2024-03-31 | $6.79 | $1.60 | +30.70% |
| Q4 2023 | 2023-12-31 | $6.13 | $0.38 | +6.54% |
| Q3 2023 | 2023-09-30 | $5.41 | -$0.43 | −7.33% |
| Q2 2023 | 2023-06-30 | $5.78 | -$0.01 | −0.16% |
| Q1 2023 | 2023-03-31 | $5.20 | -$0.58 | −10.08% |
| Q4 2022 | 2022-12-31 | $5.76 | -$0.27 | −4.53% |
| Q3 2022 | 2022-09-30 | $5.84 | -$1.38 | −19.09% |
| Q2 2022 | 2022-06-30 | $5.79 | -$1.33 | −18.68% |
| Q1 2022 | 2022-03-31 | $5.78 | $0.95 | +19.67% |
| Q4 2021 | 2021-12-31 | $6.03 | $0.65 | +12.18% |
| Q3 2021 | 2021-09-30 | $7.22 | $2.22 | +44.49% |
| Q2 2021 | 2021-06-30 | $7.12 | $2.61 | +57.76% |
| Q1 2021 | 2021-03-31 | $4.83 | $0.72 | +17.46% |
| Q4 2020 | 2020-12-31 | $5.37 | $2.78 | +107.04% |
| Q3 2020 | 2020-09-30 | $4.99 | $2.48 | +98.71% |
| Q2 2020 | 2020-06-30 | $4.52 | $1.95 | +75.83% |
| Q1 2020 | 2020-03-31 | $4.11 | $1.53 | +58.98% |
| Q4 2019 | 2019-12-31 | $2.60 | -$0.16 | −5.71% |
| Q3 2019 | 2019-09-30 | $2.51 | $0.38 | +18.05% |
| Q2 2019 | 2019-06-30 | $2.57 | $0.08 | +3.06% |
| Q1 2019 | 2019-03-31 | $2.59 | -$0.16 | −5.94% |
| Q4 2018 | 2018-12-31 | $2.75 | -$0.42 | −13.31% |
| Q3 2018 | 2018-09-30 | $2.13 | -$1.00 | −31.96% |
| Q2 2018 | 2018-06-30 | $2.49 | -$0.74 | −22.86% |
| Q1 2018 | 2018-03-31 | $2.75 | -$1.13 | −29.17% |
| Q4 2017 | 2017-12-31 | $3.18 | -$1.42 | −30.87% |
| Q3 2017 | 2017-09-30 | $3.13 | -$0.02 | −0.69% |
| Q2 2017 | 2017-06-30 | $3.23 | -$0.96 | −22.96% |
| Q1 2017 | 2017-03-31 | $3.88 | -$1.30 | −25.01% |
| Q4 2016 | 2016-12-31 | $4.59 | $0.49 | +12.00% |
| Q3 2016 | 2016-09-30 | $3.15 | -$1.37 | −30.33% |
| Q2 2016 | 2016-06-30 | $4.19 | -$0.76 | −15.30% |
| Q1 2016 | 2016-03-31 | $5.18 | $81.14 | — |
| Q4 2015 | 2015-12-31 | $4.10 | $92.90 | — |
| Q3 2015 | 2015-09-30 | $4.52 | — | — |
| Q2 2015 | 2015-06-30 | $4.95 | — | — |
| Q1 2015 | 2015-03-31 | -$75.96 | — | — |
| Q4 2014 | 2014-12-31 | -$88.80 | — | — |
Collegium Pharmaceutical book value per share trends
Over the last five fiscal years, Collegium Pharmaceutical's book value per share increased from $5.37 to $9.51, a change of $4.14. The latest reported quarter, Q2 2026, shows $9.60.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Collegium Pharmaceutical source filings ↗